Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LY2 | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 126 | uM | 10264.011 | 0.1821 | -0.4084 | 1.3983 | |
| LY2 | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 0.00805 | uM | 10264.011 | 1.0021 | 1.0030 | 1.3983 | |
| LY2 | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 5.03 | uM | 10264.011 | 0.5766 | 0.3490 | 1.3983 | |
| LY2 | HR+ | Luminal | Gemcitabine | DNA replication | DNA replication | 1.16 | uM | 10264.011 | 0.6202 | 0.4213 | 1.3983 | |
| LY2 | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 25.2 | uM | 10264.011 | 0.4063 | 0.0503 | 1.3983 | |
| LY2 | HR+ | Luminal | Carboplatin | DNA cross-linker | DNA cross-linker | 53.9 | uM | 10264.011 | 0.6811 | 0.5197 | 1.3983 | |
| LY2 | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 629 | uM | 10264.011 | 0.0859 | -0.6543 | 1.3983 | |
| LY2 | HR+ | Luminal | Gemcitabine | DNA replication | DNA replication | 5.78 | uM | 10264.011 | 0.6823 | 0.5216 | 1.3983 | |
| LY2 | HR+ | Luminal | Gemcitabine | DNA replication | DNA replication | 28.9 | uM | 10264.011 | 0.6325 | 0.4413 | 1.3983 | |
| LY2 | HR+ | Luminal | Geldanamycin | HSP90 | HSP90 | 0.032 | uM | 10264.024 | 0.7120 | 0.5147 | 1.2223 | |
| LY2 | HR+ | Luminal | Geldanamycin | HSP90 | HSP90 | 0.0064 | uM | 10264.024 | 0.9336 | 0.8906 | 1.2223 | |
| LY2 | HR+ | Luminal | Trametinib | MEK | MAPK | 0.00107 | uM | 10264.024 | 1.0250 | 1.0409 | 1.2223 | |
| LY2 | HR+ | Luminal | Trametinib | MEK | MAPK | 0.00533 | uM | 10264.024 | 0.8678 | 0.7810 | 1.2223 | |
| LY2 | HR+ | Luminal | Trametinib | MEK | MAPK | 0.000213 | uM | 10264.024 | 1.0192 | 1.0313 | 1.2223 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 10264.024 | 1.0288 | 1.0469 | 1.2223 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.0533 | uM | 10264.024 | 1.0237 | 1.0387 | 1.2223 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.00213 | uM | 10264.024 | 1.0004 | 1.0007 | 1.2223 | |
| LY2 | HR+ | Luminal | Trametinib | MEK | MAPK | 0.0267 | uM | 10264.024 | 0.9168 | 0.8628 | 1.2223 | |
| LY2 | HR+ | Luminal | Geldanamycin | HSP90 | HSP90 | 0.16 | uM | 10264.024 | 0.3764 | -0.1008 | 1.2223 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.0107 | uM | 10264.024 | 0.7777 | 0.6282 | 1.2223 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.267 | uM | 10264.024 | 0.9757 | 0.9601 | 1.2223 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 1.33 | uM | 10264.024 | 0.9447 | 0.9091 | 1.2223 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 33.3 | uM | 10264.024 | 0.6482 | 0.4027 | 1.2223 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 6.67 | uM | 10264.024 | 0.9133 | 0.8570 | 1.2223 | |
| LY2 | HR+ | Luminal | Geldanamycin | HSP90 | HSP90 | 20 | uM | 10264.024 | 0.3071 | -0.2388 | 1.2223 |